Publications
Nombela, I. et al. (2022) “BET-Independent Murine Leukemia Virus Integration Is Retargeted in Vivo and Selects Distinct Genomic Elements for Lymphomagenesis”, Microbiology Spectrum, 10(4). Available at: 10.1128/spectrum.01478-22.
Schwaller, J. (2022) “High-mobility-group protein A1 in MPN progression”, Blood, 139(18), pp. 2730–2732. Available at: 10.1182/blood.2022016145.
Schwaller, J. (2021) “MLL-AF4+ infant leukemia: a microRNA affair”, Blood, 138(21), pp. 2014–2015. Available at: 10.1182/blood.2021012818.
Tauchmann, S., Schwaller, J. (2021) “Nsd1: A lysine methyltransferase between developmental disorders and cancer”, Life, 11(9). Available at: 10.3390/life11090877.
Fagnan, A. et al. (2021) “Molecular Landscapes and Models of Acute Erythroleukemia”, HemaSphere, 5(5). Available at: 10.1097/HS9.0000000000000558.
Leonards, K. et al. (2020) “Nuclear interacting SET domain protein 1 inactivation impairs GATA1-regulated erythroid differentiation and causes erythroleukemia”, Nature Communications, 11(1), p. 2807. Available at: 10.1038/s41467-020-16179-8.
Forte, D. et al. (2020) “Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy”, Cell Metabolism, 32(5), pp. 829–843.e9. Available at: 10.1016/j.cmet.2020.09.001.
Tauchmann, S., Almosailleakh, M., Schwaller, J. (2020) “NSD1 in erythroid differentiation and leukemogenesis”, Molecular and Cellular Oncology, 7(6), p. 1809919. Available at: 10.1080/23723556.2020.1809919.
Fagnan, A. et al. (2020) “Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers”, Blood, 136(6), pp. 698–714. Available at: 10.1182/blood.2019003062.
Schwaller, J. (2020) “Learning from mouse models of MLL fusion gene-driven acute leukemia”, Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, 1863(8), p. 194550. Available at: 10.1016/j.bbagrm.2020.194550.
Fisher, J. et al. (2020) “Transforming activities of the NUP98-KMT2A fusion gene associated with myelodysplasia and acute myeloid leukemia”, Haematologica, 105(7), pp. 1857–1867. Available at: 10.3324/haematol.2019.219188.
Schwaller, J. (2020) “Role of Meningioma 1 for maintaining the transformed state in MLL-rearranged acute myeloid leukemia: Potential for therapeutic intervention?”. Available at: 10.3324/HAEMATOL.2019.246348.
Schwaller, J. (2020) “Writing Constructive Reviews for Scientific Journals”. Available at: 10.1097/HS9.0000000000000343.
Lopez, C. et al. (2019) “Ontogenic changes in hematopoietic hierarchy determine pediatric specificity and disease phenotype in fusion oncogene– driven myeloid leukemia”, Cancer Discovery, 9(12), pp. 1736–1753. Available at: 10.1158/2159-8290.CD-18-1463.
Mercher, T., Schwaller, J. (2019) “Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention”, Frontiers in Pediatrics, 7, p. 401. Available at: 10.3389/fped.2019.00401.
Kivioja, J. et al. (2019) “Dasatinib and navitoclax act synergistically to target NUP98-NSD1 +/FLT3-ITD+ acute myeloid leukemia”, Leukemia, 33(6), pp. 1360–1372. Available at: 10.1038/s41375-018-0327-2.
Skoda, R., Schwaller, J. (2019) “Dual roles of EZH2 in acute myeloid leukemia”, Journal of Experimental Medicine, 216(4), pp. 725–727. Available at: 10.1084/jem.20190250.
Fisher, J. et al. (2019) “The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning from Mouse Models”, HemaSphere, 3(1), p. e152. Available at: 10.1097/HS9.0000000000000152.
Almosailleakh, M., Schwaller, J. (2019) “Murine models of acute Myeloid Leukaemia”, International Journal of Molecular Sciences, 20(2). Available at: 10.3390/ijms20020453.
Schwaller, J. (2019) “Novel insights into the role of aberrantly expressed MNX1 (HLXB9) in infant acute myeloid leukemia”, Haematologica, 104(1), pp. 1–3. Available at: 10.3324/haematol.2018.205971.
Paczulla, A.M. et al. (2019) “Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion”, Nature, 572(7768), pp. 254–259. Available at: 10.1038/s41586-019-1410-1. edoc | Open Access
Paczulla, A.M. et al. (2019) “Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion”, Nature, 572(7770), p. E19. Available at: 10.1038/s41586-019-1475-x. edoc
Mercher, T., Schwaller, J. (2019) “Corrigendum: Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention”. Available at: 10.3389/fped.2019.00466.
Valent, P. et al. (2018) “Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts”., Haematologica, 103(10), pp. 1593–1603. Available at: 10.3324/haematol.2018.192518.
Soen, B. et al. (2018) “ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?”, HemaSphere, 2(3), p. e43. Available at: 10.1097/hs9.0000000000000043.
El, A.S. et al. (2018) “LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis”., Blood, 131(1), pp. 95–107. Available at: 10.1182/blood-2017-05-786962.
Stavropoulou, V., Peters, A., Schwaller, J. (2018) “Aggressive leukemia driven by MLL-AF9”., Molecular & cellular oncology, 5(3), p. e1241854. Available at: 10.1080/23723556.2016.1241854.
Vaia Stavropoulou, M.A. (2018) “A Novel Inducible Mouse Model of MLL-ENL-driven Mixed-lineage Acute Leukemia”, Hemasphere, 2(August), p. e51. Available at: 10.1097/hs9.00000000000000051.
Dafflon, C., Tiedt, R., Schwaller, J. (2017) “Targeting multiple nodes of MLL complexes to improve leukemia therapy”. Available at: 10.18632/oncotarget.21598.
Thirant, C. et al. (2017) “ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia”., Cancer cell, 31(3), pp. 452–465. Available at: 10.1016/j.ccell.2017.02.006.
Stavropoulou, V., Schwaller, J. (2017) “The hematopoietic precursor cell in which driver mutations occur is linked to AML aggressiveness – A potential target for personalized medicine”, Expert Review of Precision Medicine and Drug Development, 2(1), pp. 1–3. Available at: 10.1080/23808993.2017.1289065.
Dafflon, C. et al. (2017) “Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia”, Leukemia, 31(6), pp. 1269–1277. Available at: 10.1038/leu.2016.327. edoc
Stavropoulou, V. et al. (2016) “MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome”, Cancer cell, 30(1), pp. 43–58. Available at: 10.1016/j.ccell.2016.05.011. edoc
Fahrenkrog, B. et al. (2016) “Expression of Leukemia-Associated Nup98 Fusion Proteins Generates an Aberrant Nuclear Envelope Phenotype”, PloS one, 11(3), p. e0152321. Available at: 10.1371/journal.pone.0152321. edoc
Picaud, S. et al. (2016) “Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia”, Science advances, 2(10), p. e1600760. Available at: 10.1126/sciadv.1600760. edoc
Picaud, S. et al. (2015) “Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy”, Cancer research, 75(23), pp. 5106–5119. Available at: 10.1158/0008-5472.can-15-0236. edoc
Qiu, J.J. et al. (2015) “Critical role of retinoid/rexinoid signaling in mediating transformation and therapeutic response of NUP98-RARG leukemia”, Leukemia, 29(5), pp. 1153–62. Available at: 10.1038/leu.2014.334. edoc
Cermáková, K. et al. (2014) “Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia”, Cancer Research, 74(18), pp. 5139–51. Available at: 10.1158/0008-5472.can-13-3602. edoc
Arranz, L. et al. (2014) “Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms”, Nature, 512(7512), pp. 78–81. Available at: 10.1038/nature13383. edoc
Brault, L. et al. (2014) “CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia”, Leukemia, 28(3), pp. 566–76. Available at: 10.1038/leu.2013.201. edoc
Thanasopoulou, A., Tzankov, A., Schwaller, J. (2014) “Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction”, Haematologica, 99(9), pp. 1465–71. Available at: 10.3324/haematol.2013.100917. edoc
Decker, S. et al. (2014) “PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1)”, Molecular Cancer Therapeutics, 13(5), pp. 1231–45. Available at: 10.1158/1535-7163.mct-13-0575-t. edoc
Sánchez-Aguilera, A. et al. (2014) “Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis”, Cell Stem Cell, 15(6), pp. 791–804. Available at: 10.1016/j.stem.2014.11.002. edoc
Picaud, S. et al. (2013) “PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains”, Cancer Research, 73(11), pp. 3336–46. Available at: 10.1158/0008-5472.can-12-3292. edoc
Méreau, H. et al. (2013) “Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75)”, Leukemia, 27(6), pp. 1245–53. Available at: 10.1038/leu.2013.10. edoc
Méreau, H., Schwaller, J. (2013) “Trithorax and polycomb cooperation in MLL fusion acute leukemia”, Haematologica, 98(6), pp. 825–7. Available at: 10.3324/haematol.2013.084301. edoc
Walpen, T. et al. (2012) “Nuclear PIM1 confers resistance to rapamycin-impaired endothelial proliferation”, Biochemical and Biophysical Research Communications, 429(1-2), pp. 24–30. Available at: 10.1016/j.bbrc.2012.10.106. edoc
Huber, K. et al. (2012) “7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes”, Journal of Medicinal Chemistry, 55(1), pp. 403–413. Available at: 10.1021/jm201286z. edoc
Walpen, T. et al. (2012) “Loss of pim1 imposes a hyperadhesive phenotype on endothelial cells”, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 30(4), pp. 1083–96. Available at: 10.1159/000341484. edoc
Schwaller, J. (2012) “Modeling ETV6-JAK2-induced leukemia: insights from the zebrafish”, Haematologica, 97(12), pp. 1783–5. Available at: 10.3324/haematol.2012.080754. edoc
Brault, L. et al. (2012) “PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma”, British journal of cancer, 107(3), pp. 491–500. Available at: 10.1038/bjc.2012.272. edoc
Thanasopoulou, A. et al. (2012) “Loss of CCDC6 affects cell cycle through impaired intra-S-phase checkpoint control”, PLoS ONE, 7(2), p. e31007. Available at: 10.1371/journal.pone.0031007. edoc
Miduturu, C.V. et al. (2011) “High-throughput kinase profiling : a more efficient approach toward the discovery of new kinase inhibitors”, Chemistry & biology, 18(7), pp. 868–79. Available at: 10.1016/j.chembiol.2011.05.010. edoc
Skoda, R.C., Schwaller, J. (2011) “HiJAKing the methylosome in myeloproliferative disorders”, Cancer cell, 19(2), pp. 161–3. Available at: 10.1016/j.ccr.2011.01.046. edoc
Peters, A.H.F.M., Schwaller, J. (2011) “Epigenetic mechanisms in acute myeloid leukemia”, Progress in drug research, 67, pp. 197–219. Available at: 10.1007/978-3-7643-8989-5_10. edoc
Stavropoulou, V., Brault, L., Schwaller, J. (2010) “Insights into molecular pathways for targeted therapeutics in acute leukemia”, Swiss medical weekly, 140, p. w13068. Available at: 10.4414/smw.2010.13068. edoc
Liu, T. et al. (2010) “Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia”, Leukemia, 24(3), pp. 601–12. Available at: 10.1038/leu.2009.272. edoc
Brault, L. et al. (2010) “PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers”, Haematologica, 95(6), pp. 1004–15. Available at: 10.3324/haematol.2009.017079. edoc
Stavropoulou, V., Brault, L., Schwaller, J. (2010) “Insights into molecular pathways for targeted therapeutics in acute leukaemia”, Swiss Medical Weekly, 140(SEPTEMBER).
Meier, C. et al. (2009) “Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas”, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, 22(3), pp. 476–87. Available at: 10.1038/modpathol.2008.207. edoc
Mumprecht, S. et al. (2009) “Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression”, Blood : the journal of the American Society of Hematology, 114(8), pp. 1528–36. Available at: 10.1182/blood-2008-09-179697. edoc
Grundler, R. et al. (2009) “Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration”, Journal of Experimental Medicine, 206(9), pp. 1957–70. Available at: 10.1084/jem.20082074. edoc | Open Access
Jankovic, D. et al. (2008) “Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia”, Blood, 111(12), pp. 5672–82. Available at: 10.1182/blood-2007-09-108175. edoc
Tiedt, R. et al. (2008) “Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice”, Blood, 111(8), pp. 3931–40. Available at: 10.1182/blood-2007-08-107748. edoc
Went, P. et al. (2008) “Role of the tumor necrosis factor ligand APRIL in Hodgkin’s lymphoma : a retrospective study including 107 cases”, Experimental hematology, 36(5), pp. 533–4. Available at: 10.1016/j.exphem.2007.12.017. edoc
Mhawech-Fauceglia, P. et al. (2008) “Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma”, Cancer epidemiology biomarkers & prevention, 17(3), pp. 571–7. Available at: 10.1158/1055-9965.epi-07-0511. edoc
Schwaller, J., Skoda, R. (2008) “Non-transplant therapeutic strategies for patients with BCR-ABL-negative chronic myeloproliferative disorders”, in. CRC Press, pp. 217–225.
Fedorov, O. et al. (2007) “A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases”, Proceedings of the National Academy of Sciences of the United States of America, 104(51), pp. 20523–20528. Available at: 10.1073/pnas.0708800104.
Pogacic, V. et al. (2007) “Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity”, Cancer Research, 67(14), pp. 6916–6924. Available at: 10.1158/0008-5472.CAN-07-0320.
Rueda, D. et al. (2007) “Bcl10 controls TCR- and FCγR-induced actin polymerization”, Journal of Immunology, 178(7), pp. 4373–4384. Available at: 10.4049/jimmunol.178.7.4373.
Schwaller, J. et al. (2007) “Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness”, Blood, 109(1), pp. 331–338. Available at: 10.1182/blood-2006-02-001800.
Schwaller, J. et al. (2007) “Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin’s Disease [11]”, Leukemia, 21(6), pp. 1324–1327. Available at: 10.1038/sj.leu.2404627.
Mhawech-Fauceglia, P. et al. (2006) “The source of APRIL up-regulation in human solid tumor lesions”, Journal of Leukocyte Biology, 80(4), pp. 697–704. Available at: 10.1189/jlb.1105655.
Adam, M. et al. (2006) “Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL”, Cancer Research, 66(7), pp. 3828–3835. Available at: 10.1158/0008-5472.CAN-05-2309.
Mhawech-Fauceglia, P., Cheney, R., Schwaller, J. (2006) “Genetic alterations in urothelial bladder carcinoma: An updated review”, Cancer, 106(6), pp. 1205–1216. Available at: 10.1002/cncr.21743.
Schwaller, J. (2006) “siRNA-mediated inhibition of E2A-PBX1 reduces EB-1 and Wnt16b expression in 697 pre-B leukemia cells”., Haematologica, 91(6), p. 724.
Chalandon, Y., Schwaller, J. (2005) “Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies”, Haematologica, 90(7), pp. 949–968.
Ho, L. et al. (2005) “MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-κB-dependent proliferative advantage and resistance against FAS-induced cell death in B cells”, Blood, 105(7), pp. 2891–2899. Available at: 10.1182/blood-2004-06-2297.
Mhawech, P. et al. (2005) “Downregulation of 14-3-3σ in ovary, prostate and endometrial carcinomas is associated with CpG island methylation”, Modern Pathology, 18(3), pp. 340–348. Available at: 10.1038/modpathol.3800240.
Pelte, M. et al. (2004) “Pro-opiomelanocortin expression in a metastatic breast carcinoma with ectopic ACTH secretion”, Breast Journal, 10(4), pp. 350–354. Available at: 10.1111/j.1075-122X.2004.21467.x.
Mhawech, P. et al. (2004) “Human achaete-scute homologue (hASH1) mRNA level as a diagnostic marker to distinguish esthesioneuroblastoma from poorly differentiated tumors arising in the sinonasal tract”, American Journal of Clinical Pathology, 122(1), pp. 100–105. Available at: 10.1309/QD0K9Q1JBH6B5GQQ.
Borisch, B. et al. (2003) “ALK-positive anaplastic large-cell lymphoma: Strong T and B anti-tumour responses may cause hypocellular aspects of lymph nodes mimicking inflammatory lesions”, European Journal of Haematology, 71(4), pp. 243–249. Available at: 10.1034/j.1600-0609.2003.00144.x.
Anastasiadou, E., Schwaller, J. (2003) “Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: An update”, Current Opinion in Hematology, 10(1), pp. 40–48. Available at: 10.1097/00062752-200301000-00007.
Roos, J. et al. (2001) “Expression of TCL1 in hematologic disorders”, Pathobiology, 69(2), pp. 59–66. Available at: 10.1159/000048758.
Andreasson, P. et al. (2001) “The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo”, Cancer Genetics and Cytogenetics, 130(2), pp. 93–104. Available at: 10.1016/S0165-4608(01)00518-0.
Schwaller, J. et al. (2001) “H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor β gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22)”, Blood, 97(12), pp. 3910–3918. Available at: 10.1182/blood.V97.12.3910.
Frantsve, J. et al. (2001) “Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation”, Molecular and Cellular Biology, 21(10), pp. 3547–3557. Available at: 10.1128/MCB.21.10.3547-3557.2001.
Liu, Q. et al. (2000) “Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia”, EMBO Journal, 19(8), pp. 1827–1838. Available at: 10.1093/emboj/19.8.1827.
Gähler, A. et al. (2000) “Interleukin-8 expression by fetal and neonatal pulmonary cells in hyaline membrane disease and amniotic infection”, Pediatric Research, 48(3), pp. 299–303. Available at: 10.1203/00006450-200009000-00006.
Pabst, T. et al. (2000) “Divergent Expression of Cclin-Dependent Kinase Inhibitors (CKI) And p14ARF/p16β in Non-Hodgkin’s Lymphomas and Chronic Lymphocytic Leukemia”, Leukemia and Lymphoma, 37(42130), pp. 639–648. Available at: 10.3109/10428190009058520.
Schwaller, J. et al. (2000) “Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2”, Molecular Cell, 6(3), pp. 693–704. Available at: 10.1016/S1097-2765(00)00067-8.
Tomasson, M. et al. (1999) “TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor”, Blood, 93(5), pp. 1707–1714. Available at: 10.1182/blood.v93.5.1707.
Schwaller, J. et al. (1998) “Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes”, EMBO Journal, 17(18), pp. 5321–5333. Available at: 10.1093/emboj/17.18.5321.
Schwaller, J. et al. (1997) “Comparative detection and quantitation of human CDK inhibitor mRNA expression of p15(INK4B), p16(INK4A), p16β, p18(INK4C), p19(INK4D), p21(WAF1), p27(KIP1) and p57(KIP2) by RT-PCR using a polycompetitive internal standard”, British Journal of Haematology, 99(4), pp. 896–900. Available at: 10.1046/j.1365-2141.1997.4863289.x.
Schwaller, J. et al. (1997) “Expression and regulation of G1 cell-cycle inhibitors (p16(INK4A), p15(INK4B), p18(INK4C), p19(INK4D) in human acute myeloid leukemia and normal myeloid cells”, Leukemia, 11(1), pp. 54–63. Available at: 10.1038/sj.leu.2400522.
Schwaller, J. et al. (1997) “Up-regulation of p21(WAF1) expression in myeloid cells is activated by the protein kinase C pathway”, British Journal of Cancer, 76(12), pp. 1554–1557. Available at: 10.1038/bjc.1997.595.
Pabst, T. et al. (1996) “Frequent clonal loss of heterozygosity but scarcity of microsatellite instability at chromosomal breakpoint cluster regions in adult leukemias”, Blood, 88(3), pp. 1026–1034. Available at: 10.1182/blood.v88.3.1026.bloodjournal8831026.
Pabst, T. et al. (1996) “Detection of microsatellite markers in leukaemia using DNA from archival bone marrow smears”, British Journal of Haematology, 95(1), pp. 135–137. Available at: 10.1046/j.1365-2141.1996.7622385.x.
Takeuchi, S. et al. (1995) “Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood”, Blood, 86(2), pp. 755–760. Available at: 10.1182/blood.v86.2.755.bloodjournal862755.
Schwaller, J. et al. (1995) “Interleukin-12 expression in human lymphomas and nonneoplastic lymphoid disorders”, Blood, 85(8), pp. 2182–2188. Available at: 10.1182/blood.v85.8.2182.bloodjournal8582182.
Schwaller, J. et al. (1995) “Posttranscriptional Stabilization Underlies p53-independent Induction of p21WAF1/CIP1/SDI1 in Differentiating Human Leukemic Cells”, Journal of Clinical Investigation, 95(3), pp. 973–979. Available at: 10.1172/JCI117806.
Nakamaki, T. et al. (1995) “Structural integrity of the cyclin‐dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias”, British Journal of Haematology, 91(1), pp. 139–149. Available at: 10.1111/j.1365-2141.1995.tb05259.x.
Stallmach, T. et al. (1995) “Cytokine production and visualized effects in the feto-maternal unit: Quantitative and topographic data on cytokines during intrauterine disease”, Laboratory Investigation, 73(3), pp. 384–392.
Schwaller, J. et al. (1993) “A myeloblastin/proteinase-3 cDNA clone identifies a BglII and a PvuII restriction fragment length polymorphism”, Human Genetics, 92(5), p. 525. Available at: 10.1007/BF00216465.
Walpoth, B. et al. (1993) “Current problems with autologous blood supply”, Transfusion Medicine and Hemotherapy, 20(6), pp. 316–326. Available at: 10.1159/000222867.